Vascular Access Surveillance: Flow Monitoring & Preemptive Intervention

The Surveillance Evidence

Landmark RCTs (the 2000s-era trials): surveillance with access flow (Transonic) + preemptive angioplasty reduced AVG thrombosis by 30-60% and access loss by 20-40% in grafts. AVF data showed smaller but consistent benefits.

The counter-evidence: a 2012-2017 era trial (AVF surveillance) found no reduction in thrombosis with routine flow-based surveillance — attributed to: (a) high event rates in the control arm receiving opportunistic intervention, (b) surveillance-detected stenoses that wouldn't have caused thrombosis (the 'over-treatment' concern), (c) imaging thresholds not matched to intervention capability.

KDOQI 2019 resolution: routine surveillance is CONDITIONAL (weak recommendation) — but monthly PHYSICAL EXAM is unconditionally recommended for every session. The practical synthesis: systematic physical exam is mandatory; flow-based surveillance is valuable for high-risk patients and access types (AVG, high-risk AVF, prior stenosis).

The Physical Exam Protocol (Every Session)

Look: skin integrity, aneurysm/pseudoaneurysm (size change, skin thinning), edema, redness, collateral veins (central stenosis sign), arm size asymmetry.

Listen: continuous thrill throughout systole AND diastole (high-pitched, discontinuous thrill suggests stenosis downstream of exam point).

Feel: thrill strength along the access, pulse character (weak pulse + strong thrill = inflow stenosis; strong pulse + weak thrill = outflow stenosis), augmentation test (compression distal → pulse augmentation assessment), and the arm elevation test.

Documentation: exam findings logged per session (ZuvFlo's access exam template) — trend data enables early detection of change patterns (e.g., progressive thrill weakness over 3 sessions).

Flow Monitoring (Qa) Protocols

Measurement: Transonic ultrasound dilution (in-session, 5 min) or Doppler ultrasound (scheduled). Frequency: monthly (KDOQI-era standard) or quarterly for stable accesses — cost-optimized per center policy.

Thresholds for referral: Qa <600 mL/min (AVF) or <500 mL/min (AVG) with clinical correlate, or >25% decrease from baseline. Trending matters more than single values — a 20-25% drop over 2 consecutive measurements warrants fistulography.

Metrics to track per access: baseline Qa, monthly trend, stenosis detection rate, intervention rate, and post-intervention primary patency — facility-level reports identify underperforming accesses early.

The Complete Program

Program elements: (1) monthly physical exam (mandatory, documented), (2) flow monitoring schedule (monthly/quarterly per risk tier), (3) referral protocol (fistulogram within 2-4 weeks of threshold), (4) intervention capability or partnership (angioplasty/AVF repair), (5) post-intervention surveillance resumption, (6) quarterly program metrics review.

Risk-tiering: low (mature AVF, Qa stable) → quarterly flow; medium (AVG, prior stenosis, diabetic) → monthly flow; high (recent angioplasty, thrombosis history) → monthly flow + clinical flag review.

Outcome measurement: thrombosis rate per access-year (target <0.5), access survival (12-month primary patency targets: AVF 50-60%, AVG 40-50%), and catheter days avoided. ZuvFlo's access tracking module automates this registry.